JITC

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
Vicky Makker, Matthew H Taylor, Carol Aghajanian, Allen L Cohn, Marcia S Brose, Christopher Di Simone, Zhu Alexander Cao, Leah Suttner, Andrey Loboda, Razvan Cristescu, Petar Jelinic, Robert Orlowski, Lea Dutta, Junji Matsui, Corina E Dutcus, Yukinori Minoshima, Mark J Messing

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e007929; DOI: 10.1136/jitc-2023-007929
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
Peter Galle, Richard S Finn, Catherine Ruth Mitchell, Kerigo Ndirangu, Zahra Ramji, Gabrielle Sophie Redhead, David J Pinato

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e008266; DOI: 10.1136/jitc-2023-008266
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors
Xiang Li, Yangzhong Zhou, Bing Xu, Yunhe Qin, Jiuliang Zhao, Mengtao Li, Jiachen Xu, Guanqiao Li

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e007959; DOI: 10.1136/jitc-2023-007959
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4⁺ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, Natalia Sigal, Li-Chun Cheng, William D Chronister, Shane A Evans, John Marsiglio, Berit Gibson, Umang Swami, Alyssa Erickson-Wayman, Jordan P McPherson, Yoko S Derose, Annaleah Larson Eliason, Carlos O Medina, Ramji Srinivasan, Matthew H Spitzer, Ngan Nguyen, John Hyngstrom, Siwen Hu-Lieskovan

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e008056; DOI: 10.1136/jitc-2023-008056
Corticosteroid-resistant immune-related adverse events: a systematic review
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Läubli

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e007409; DOI: 10.1136/jitc-2023-007409
Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer
Gulfem D Guler, Yuhong Ning, Ceyda Coruh, Giuliana P Mognol, Tierney Phillips, Maryam Nabiyouni, Kyle Hazen, Aaron Scott, Wayne Volkmuth, Samuel Levy

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e008028; DOI: 10.1136/jitc-2023-008028
Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites
Tara Muijlwijk, Dennis N L M Nijenhuis, Sonja H Ganzevles, Arjen Brink, Changlin Ke, Joseph N Fass, Venkatesh Rajamanickam, C René Leemans, Yoshinobu Koguchi, Bernard A Fox, Jos B Poell, Ruud H Brakenhoff, Rieneke van de Ven

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e007573; DOI: 10.1136/jitc-2023-007573
Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research
Raphael Yip, Gaston Arnolda, Klay Lamprell, Bróna Nic Giolla Easpaig, Renuka Chittajallu, Geoff Delaney, Ian Olver, Winston Liauw, Jeffrey Braithwaite

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e007555; DOI: 10.1136/jitc-2023-007555
Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow
Yan Li, Xueyan Liang, Huijuan Li, Xiaoyu Chen

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e007931; DOI: 10.1136/jitc-2023-007931
Gasdermin-mediated pyroptosis confers anticancer immunity
Wu Lin, Ben Lin, Quan Zhou, Lisong Teng

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e008162; DOI: 10.1136/jitc-2023-008162

Main menu

JITC

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

JITC

Pages